Advertisement

Anticancer drugs

  • Corinne Isnard-Bagnis
  • Vincent Launay-Vacher
  • Svetlana Karie
  • Gilbert Deray

Nephrotoxicity is an inherent adverse effect of certain anticancer drugs. Antineoplastic drugs have a narrow therapeutic index and the amount of drug necessary to produce a significant reduction in tumor burden usually produces significant nephrotoxicity. The dosage used in clinical trials represents often the maximum tolerated doses determined during phase I drug evaluation. Greater toxicity is acceptable during curative therapy than during palliative therapy. But cancer patients often exhibit excretory reduced organ function. Modulation of pharmacokinetics and pharmacodynamics of these drugs in cancer patient is therefore necessary in order to improve tolerance. Patients with malignancies are particularly vulnerable to development of renal abnormalities. Conversely, patients with renal abnormalities who have undergone kidney transplantation are at high risk for malignancy. Clinical syndromes of renal involvement are diverse and sometimes insidious. This chapter focuses on the major anticancer drugs and their renal consequences. Despite the recent physiopathological advances in understanding the mechanism of anticancer drug nephrotoxicity, prevention still relies on drug dosage decrease, and active screening for renal abnormalities as part of the usual biological work up in patients treated with anticancer drugs (Table 1).

Keywords

Vascular Endothelial Growth Factor Clin Oncol Acute Renal Failure Hemolytic Uremic Syndrome Renal Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Safirstein RL. Anticancer drugs. In Clinical Nephrotoxins, Debroe ME, Porter GA, Bennett WM, Verpoten GA. [Editors]. Kluwer Academic Publ. Dordrecht, 1998: 261-271.Google Scholar
  2. 2.
    Meijer S, Mulder NH, Sleijfer DT, de Jong PE, Sluiter WJ, Schraffordt Koops H, van der Hem GK. Nephrotoxicity of cis-diam- minedichloride platinum [CDDP] during remission-induction and maintenance chemotherapy of the testicular carcinoma. Cancer Chemother Pharmacol 1982; 8: 27-30.PubMedGoogle Scholar
  3. 3.
    Brock PR, Koliouska DE, Baratt TM, Yeomans E, Pritchard J. Partial reversibili ty of cisplatin nephrotoxicity in children. J Pediatric 1991; 118: 531-4.Google Scholar
  4. 4.
    Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiamine platinum by WR 272l without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57-64.PubMedGoogle Scholar
  5. 5.
    Borch RF, Pleasants ME. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat renal model. Proc Natl Acad Sci USA 1979; 76: 6611-4.PubMedGoogle Scholar
  6. 6.
    Berry J-P, Pauwells C, Tlouzeau S, Lespinats G. Effect of Selenium in combina tion with cis-diamminedichloroplatinum [II] in the treatment of murine fibrosarcoma. Cancer Res 1984; 44: 2864-8.PubMedGoogle Scholar
  7. 7.
    Citkovic E, Hayes DM, Golbey RB, Krakoff IH. Cisplatin-nephrotoxicity: diethyldithiocarbomate, WR2721 or just water. J Clin Oncol 1991; 9: 707-9.Google Scholar
  8. 8.
    Litterst CL, Torres IJ, Guarino AM. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intra- venous administration of cis-DDP[II]. J Clin Hemat Oncol 1977; 7: 169-78.Google Scholar
  9. 9.
    Safirstein R, Daye M, Miller P, Guttenplan J. Renal disposition and metabolism of liganded platinum: implications to toxicity. Fed Proc 1980; 40: 651AGoogle Scholar
  10. 10.
    Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int 1984; 25: 753-8.PubMedGoogle Scholar
  11. 11.
    Jacobs C, Kalman SM, Tretton M, Weiner MW. Renal handling of cis-diammine dichloroplatinum [II]. Cancer Treat Rep 1980; 64: 1223-6.PubMedGoogle Scholar
  12. 12.
    Levi J, Jacobs C, Kalman S, McTigue M, Weiner MWJ. Mechanism of cis-plati num nephrotoxicity I. Effects on sulfhydryl groups in rat kidneys. Pharmacol Exp Ther 1980; 213: 545-50.Google Scholar
  13. 13.
    Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity insights into mechanism. Int J Andrology 1987; 10: 325-46.Google Scholar
  14. 14.
    Safirstein RL, Daye M, Guttenplan JB. Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Letters 1983; 18: 329-38.PubMedGoogle Scholar
  15. 15.
    Bradley LJN, Yacema KJ, Lippard SJ, Essigmann JM. Mutagenicity and genoto xicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplati num [II]. Biochemistry 1993; 32: 982-8.PubMedGoogle Scholar
  16. 16.
    Greene MH. Is cisplatin a human carcinogen ? J Natl Cancer Inst 1992; 84: 306-12.PubMedGoogle Scholar
  17. 17.
    Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985, 249: F490-496.PubMedGoogle Scholar
  18. 18.
    Hutchinson FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen G. Renal salt-wasting in patients treated with cisplatin. Ann Intern Med. 1988, 108:21-5.Google Scholar
  19. 19.
    Schilsky Rl, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cis-diamminedichloroplatinum II. Ann Intern Med 1979; 90: 929-31.PubMedGoogle Scholar
  20. 20.
    Schilsky RL, Barlock A, Ozols RF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Reports 1982; 66: 1767-9.Google Scholar
  21. 21.
    Mavichak v, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomag- nesemia in rats. Kidney Int 1985; 28: 914-21.PubMedGoogle Scholar
  22. 22.
    Swainson CP, Colls BM, Fitzharris BM. Cisplatinium and distal renal tubule toxicity. N Z Med J, 1985, 98:375-378.PubMedGoogle Scholar
  23. 23.
    Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity insights into mechanism. Int J Andrology 1987; 10: 325-46.Google Scholar
  24. 24.
    Schor N, Ichikawa I, Rennke HG, Troy JL, Brenner BM. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 1981; 19: 288-92.PubMedGoogle Scholar
  25. 25.
    Gordon JA, Gattone VH. Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 1986; 250: F991-8.PubMedGoogle Scholar
  26. 26.
    Brady HR, Kone BC, Stroniski ME, Zeidel ML, Giebisch G, Gullans SR. Mitochondrial injury: an early event in cisplatin-toxicity to renal proximal tubules. Am J Physiol 1990; 258: F1181-7.PubMedGoogle Scholar
  27. 27.
    Harder HC, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int J Cancer 1970; 6: 207-16.PubMedGoogle Scholar
  28. 28.
    Howle JA, Gale GR. Cis-dichlorodiammine platinum II persistent and selective inhibition of deoxyribonucleic acid synthesis in vitro. Biochem Pharmacol 1970; 19: 2757-62.PubMedGoogle Scholar
  29. 29.
    Munchausen LL, Rahn RO. Biological and chemical effects of cis-dichlorodiammineplatinum [II] on DNA. Cancer Chemother Rep 1975; 59: 643-6.PubMedGoogle Scholar
  30. 30.
    Roberts JJ, Prascoe JM. Cross linking of complementary strands of DNA in mam malian cells by antitumor platinum compounds. Nature 1972; 235: 282-4.PubMedGoogle Scholar
  31. 31.
    Zwelling LA, Anderson T, Kohn KW. DNA-protein and DNA interstrand cross-lin king by cis- and trans platinum [II] Diamminedichlo- ride in Ll2lO mouse leukemia cells and relation to cytotoxicity. Cancer Res 1979; 39: 365-9.PubMedGoogle Scholar
  32. 32.
    Fraval HNA, Rawlings CJ, Roberts JJ. Increased sensitivity of UV repair deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus leuteus. Mutat Res 1978; 51: 12l-32.Google Scholar
  33. 33.
    Safirstein R, Zelent AZ, Gordon R. Cisplatin-nephrotoxicity: new insights into mechanisms. In: Hacker MP, Lazo JS, Tritton TR, editors. Organ directed toxicities of anticancer drugs. Boston: Martinus Nijhof, 1988: 172-89.Google Scholar
  34. 34.
    Madias NE, Harrington JT. Platinium nephrotoxicity. Am J Med 1978; 65: 307-14.PubMedGoogle Scholar
  35. 35.
    Goldstein RS, Mayor GH. Minireview: the nephrotoxicity of cisplatin. Life Sci 1983; 32: 685-90.PubMedGoogle Scholar
  36. 36.
    Heidemann HTH, Gerkens JF, Jackson EK, Branch RA. Attenuation of cisplatin-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn-Schmiedeberg’s Arch Pharmacol 1985; 329: 201-5.Google Scholar
  37. 37.
    Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IA. High dose cisplatinium diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81.PubMedGoogle Scholar
  38. 38.
    tark JJ, Howell SB. Nephrotoxicity of cisplatinium [II]-dichlorodiammine. Clin Pharmacol Ther 1978; 23: 461-6.Google Scholar
  39. 39.
    Einhorn LH, Donohue J. Cis diammine dichloroplatinium, uniblastine and gleomycine combination chemotherapy in dissemi- nated testicular cancer. Ann Intern Med. 1977. 87:293.PubMedGoogle Scholar
  40. 40.
    Cvitkovic B, Spaulding J, Bethune V, Martin J, Whitemore WF. Improvement of cis-dichlorodiammineplatinum therapeutic index in an animal model. Cancer 1977; 39: 1357-61.PubMedGoogle Scholar
  41. 41.
    Pera MF Jr, Zook BC, Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammine platinum [II] in rats. Cancer Res 1979; 29: 1269-78.Google Scholar
  42. 42.
    Litterst CL. Alterations in the toxicity of cis- dichlorodiammine platinum II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Appl Pharmacol 1981; 61: 99-108.Google Scholar
  43. 43.
    Lehane D, Winston A, Gray R, Daskal Y. The effect of diuretic pretreatment on clinical morphological and ultrastructural cis-plati- nium induced nephrotoxicity. Int J Radiation Oncology Biol Phys 1979; 5: 1393-9.Google Scholar
  44. 44.
    All-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 1982; 66: 31-5.Google Scholar
  45. 45.
    Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinium [II] by a 5-day continuous infusion. Cancer 1984; 53: 837-40.PubMedGoogle Scholar
  46. 46.
    Haas A, Anderson L, Lad T. The influence of aminoglycosides on the nephrotoxicity of cis-diammine-chloroplatinium in cancer patients. J Infect Dis 1983; 147: 363.PubMedGoogle Scholar
  47. 47.
    Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. Acute renal failure after cis-dichlorodiammine-platinium [II] and gen- tamicin-cephalotin therapies. Cancer Treat Rep 62: 693Google Scholar
  48. 48.
    Jongejan HTM, Provost AP, Molenar JC. Potentiation of cis-diamminedichloroplatinium nephrotoxicity by amikacin in rats. Cancer Chemother Pharmacol 1988; 22: 178-80.PubMedGoogle Scholar
  49. 49.
    Bregman CL, Williams PD. Comparative nephrotoxicity of carboplatin and cisplatin in combination with actinomycin. Cancer Chemother Pharmacol 1986.Google Scholar
  50. 50.
    Hirosawa A, Niitani H, Hayashibara K, Tsubo IE. Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammine platinium and vindesine. Cancer Chemother Pharmacol 1989; 23: 255-8.PubMedGoogle Scholar
  51. 51.
    Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, Yon J, Green M. Intraperi toneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845-51.PubMedGoogle Scholar
  52. 52.
    Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacity of odansetron and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 1990; 322[12]: 810-5.PubMedGoogle Scholar
  53. 53.
    Boven E, Van der Vijgh WJF, Nauta MM, Schlüper HMM, Pinedo HM. Comparative activity and distribution studies of five platinium analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Research, 45:86-90, 1985PubMedGoogle Scholar
  54. 54.
    Gormley PE, Bull JM, LeRoy AF, Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979 Mar;25[3]:351-7PubMedGoogle Scholar
  55. 55.
    Siddik ZH, Jones M, Boxall FE, Harrap KR. Comparative distribution and excretion of carboplatin and cisplatin in mice Cancer Chemother Pharmacol. 1988;21[1]:19-24Google Scholar
  56. 56.
    Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW. Blood clearance of radioactively labeled cis-diammine 1, 1-cyclobutane dicarboxylate platinum [II] [CBDCA] in cancer patients. Cancer Chemother Pharmacol. 1983;11[1]:5-7PubMedGoogle Scholar
  57. 57.
    Elferink F, van der Vijgh WJ, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986 Apr;32[4]:641-5PubMedGoogle Scholar
  58. 58.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicar- boxylate platinum[II] in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44[4]:1693-7PubMedGoogle Scholar
  59. 59.
    Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC. Phase I clinical trial and pharmacokinetics of carboplatin [NSC 241240] by single monthly 30-minute infusion. Cancer. 1986 Jan 15;57[2]:222-5PubMedGoogle Scholar
  60. 60.
    Trump DL, Elson P, Brodovsky H, Vogl SE. Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group Study. Cancer Treat Rep. 1987 Oct;71[10]:989-90PubMedGoogle Scholar
  61. 61.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine[1, 1-cyclobutanedicarboxylato]platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44[11]:5432- 8PubMedGoogle Scholar
  62. 62.
    Gaver RC, George AM, Deeb G. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin. Cancer Chemother Pharmacol. 1987;20[4]:271-6Google Scholar
  63. 63.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicar- boxylate platinum[II] in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44[4]:1693-7PubMedGoogle Scholar
  64. 64.
    Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dos- age: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7[11]:1748-56PubMedGoogle Scholar
  65. 65.
    Martinez F, Deray G, Dubois M, Beaufils H, Jacquiaud C, Bourbouze R, Benh mida M, Jaudon MC, Jacobs C. Comparative nephro- toxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs 1993; 4: 85-90.PubMedGoogle Scholar
  66. 66.
    Levine BS, Henry MC, Port CD, Richter WR, Urbanek MA. Nephrotoxic potential of cis-diamminedichloroplatinum and four analogs in male Fischer 344 rats. J Natl Cancer Inst. 1981 Jul;67[1]:201-6PubMedGoogle Scholar
  67. 67.
    Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36PubMedGoogle Scholar
  68. 68.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine[1, 1-cyclobutanedicarboxylato]platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44[11]:5432-8PubMedGoogle Scholar
  69. 69.
    Reed E, Jacob J. Carboplatin and renal dysfunction. Ann Intern Med. 1989 Mar 1;110[5]:409PubMedGoogle Scholar
  70. 70.
    Gore ME, Calvert AH, Smith LE. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escala- tion study. Eur J Cancer Clin Oncol. 1987 Sep;23[9]:1391-7PubMedGoogle Scholar
  71. 71.
    Sleijfer DT, Smit EF, Meijer S, Mulder NH, Postmus PE. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989 Jul;60[1]:116-20PubMedGoogle Scholar
  72. 72.
    Schuler U, Ehninger G and Wagner T. Repeated high_dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol. 20:248-252, 1987PubMedGoogle Scholar
  73. 73.
    Bagley CM, Bostick FW and De Wita. Clinical pharmacology of cyclophosphamide. Cancer Res. 88226-233, 1978Google Scholar
  74. 74.
    Struck RF, Kirk M, C, Mellet LB, el Dareer S and Hill DL. Urinary metabolites of the antitumor agent cyclophosphamide. Mol Pharmacol 7:519-529, 1971PubMedGoogle Scholar
  75. 75.
    Dooley JS, James CA, Rogers HJ and Stuart-Harris. Biliary elimination of cyclophosphamide in man. Cancer Chemother Pharmacol, 9:26-29, 1982PubMedGoogle Scholar
  76. 76.
    Juma FD, Rogers HJ, Trounce JR. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol. 8:209-217, 1979PubMedGoogle Scholar
  77. 77.
    Mouridsen HT, and Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 86:409-414, 1975Google Scholar
  78. 78.
    Brock N, Pohl J, and stekarJ. Studies of the urotoxicity of oxazophosphorine cytostatics and its prevention. Eur J Cancer. 17:595-607, 1981PubMedGoogle Scholar
  79. 79.
    Droller MJ, Sral R and Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology, 20:256-258, 1982PubMedGoogle Scholar
  80. 80.
    Link H, Neef V, Niethammer D and Wilms K. Prophylaxis of haemorrhagic cystatis due to cyclophosphamide-conditioning for bone marrow transplantation. Blut, 48:329-330, 1981Google Scholar
  81. 81.
    Ann Intern Med 106:79-94, 1987Google Scholar
  82. 82.
    Philips FS, Sternberg SS, Cronin AP, and Vidal PM. Cyclophosphamide and urinary bladder toxicity. Cancer Res. 21:1577-1589, 1961PubMedGoogle Scholar
  83. 83.
    Bode U, Seif SM, and Levin AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol 8: 295-303, 1980PubMedGoogle Scholar
  84. 84.
    De Fronzo RA, Colvin OM, Braine H, Robertson GL, and Davis PJ. Cyclophosphamide and the kidney. Cancer 33:483-491, 1974Google Scholar
  85. 85.
    Bode U, Seif SM, Levin AS. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med Pediatr Oncol, 8:295-303, 1980PubMedGoogle Scholar
  86. 86.
    Skinner R, Sharkey IM, Pearson ADJ, et al. Ifosfamide, Mesna and nephrotoxicity in children. J Clin Oncol 11:173-190, 1993.PubMedGoogle Scholar
  87. 87.
    Kaijser G, Bejnen J, Bult A, and Underberg W. Ifosfamide metabolism and pharmacokinetics. Anticancer Res 14:517-532, 1994PubMedGoogle Scholar
  88. 88.
    Boos J, Welslau U, Ritter J, Blaschke G and Schellong G. Urinary excretion of the enantiomers of Ifosfamide and its inactive me- abolites in children. Cancer Chemother Pharmacol 28:455-460, 1991PubMedGoogle Scholar
  89. 89.
    Mohrmann M, Pauli A, Ritzer M, Schonfeld B, Seifert B and Brandis M. Inhibition of sodium-dependent transport systems in LLC- PK1 cells by metabolites of ifosfamide. Renal Physiol Biochem 15, 289-301, 1992PubMedGoogle Scholar
  90. 90.
    Mohrmann M, Ansorge S, Schmich U, Schonfeld B, and Brandis M. Toxicity of Ifosfamide, cyclophosphamide and their metabolites in tubular cells in culture. Pediatr Nephrol 8:157-163, 1994PubMedGoogle Scholar
  91. 91.
    Zamlauski-Tucker M, Morris M, and Springate: Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the per- fused rat kidney. Toxicol App Pharmacol 129:170-175, 1994Google Scholar
  92. 92.
    Allen LM, Creaven PJ, and Nelson RL. Studies on the human pharmacokinetics of Ifosfamide [NSC-109724]. Cancer Treat Rep, 60:451-458, 1976PubMedGoogle Scholar
  93. 93.
    Springate J, Zamlauski-Tucker M, Lu H, and ChanKK. Renal Clearance of Ifosfamide. Drug Metab and Dispos, 29, 9:1081-1082, 1997Google Scholar
  94. 94.
    Suarez A, McDowell H, Niaudet P, Comoy E, and Flamant F. Long term follow up of Ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an international society of pediatric oncology report. J Clin Oncol, 9: 2177-2182, 1991PubMedGoogle Scholar
  95. 95.
    Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, Hancock ML. Ifosfamide, Fanconi’s syndrome and reickets. J Clin Oncol 9:1495-1499, 1991PubMedGoogle Scholar
  96. 96.
    Moncrieff M, and Foot A. Fanconi syndrome after Ifosfamide. Cancer Chemother Pharmacol, 23:121-122, 1989PubMedGoogle Scholar
  97. 97.
    Skinner R, Sharkey IM, Pearson ADJ and Craft AW. Ifosamide, mesna and nephrotoxicity in children. J Clin Oncol. 11:173-190, 1993PubMedGoogle Scholar
  98. 98.
    Brock N, Pohl J and Stekar J. Studies on urotoxicity of oxazophosphorine cytostatics and its prevention. Eur J Cancer 17:595-607, 1981PubMedGoogle Scholar
  99. 99.
    Van Dyck JJ, Falkson HC, Van der Merwe AM, and Falkson G. Unexpected toxicity in patients treated with ifosfamide. Cancer Res 32: 921-924, 1972Google Scholar
  100. 100.
    Falkson G, Van Dick JJ, Stapelberg R and Falkson HC. Mesnum as protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmacol 9:81-84, 1982PubMedGoogle Scholar
  101. 101.
    Stuart-Harris R, Harper PG, Kaye SB, and Wiltsaw E. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rep 10[suppA]:163-164, 1988Google Scholar
  102. 102.
    Newbury-Ecob RA, Noble VW, Barbor PRH. Ifosfamide-induced Fanconi syndrome. Lancet 2, 1328, 1989Google Scholar
  103. 103.
    Patterson WP, Khojasteh A. Ifosfamide-induced renal tubular defects. Cancer 63:649651, 1989Google Scholar
  104. 104.
    Stuart-Harris RC, Harper PJ, Parson CA and coll. High-dose alkylation therapy using Ifosfamide infusion with Mesna in the treat- ment of adult soft-tissue sarcoma. Cancer Chemother Pharmacol, 11:69-74, 1983PubMedGoogle Scholar
  105. 105.
    Willemse PHB, De Jong PE, Elema JD, Mulder NH. Severe renal failure following high-dose Ifosfamide and Mesna. Cancer Chem- other Pharmacol, 23:329-330, 1989Google Scholar
  106. 106.
    Elias AD, Eder JP, Shea T, Begg C, Frei E III, Antman K. High-dose Ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol, 8: 170-178, 1990PubMedGoogle Scholar
  107. 107.
    Rougier P, Mitry E. Digestion; Chemotherapy in the treatment of neuroendocrine malignant tumors, 62 Suppl 1:73-8, 2000Google Scholar
  108. 108.
    Bhuyan BK, Kuentzel SL, Gray LG, Fraser TJ, Wallach D and Neil GL. Tissue distribution of streptozotocin [NCS-85998]. Cancer Chemother Rep. 58:157-165, 1974PubMedGoogle Scholar
  109. 109.
    Adolphe AB, Glasofer ED, Troetel WM, Ziegenfuss J, Stambaugh JE, Weiss AJ, and Manthei RW. Fate of streptozotocin [NSC-85998] in patients with advanced cancer. Cancer Chemother Rep. 59:547-556, 1975PubMedGoogle Scholar
  110. 110.
    Schein PS, O’Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, Wiernik JL, Ziegler PH, and DeVita VT. Clinical antitumor activity and toxicity of streptozotocin [NSC-85998]. Cancer 84:993-1000, 1974Google Scholar
  111. 111.
    Myerowitz RL, Sartiano GP, and Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin. Cancer 88:1550-1555, 1976Google Scholar
  112. 112.
    Perry DJ, and Weiss RB. Nephrotoxicity of streptozotocin. Ann Int Med 96:122, 1982PubMedGoogle Scholar
  113. 113.
    Sadoff L. Nephrotoxicity of Streptozotocin [NSC-85998]. Cancer Chemother. Rep 54:457-459, 1970Google Scholar
  114. 114.
    Moertel CG, Reitemeir RJ, Schutt AJ, and Hahn RG. Phase II study of streptozotocin [NSC-85998] in the treatment of advanced gastro-intestinal cancer. Cancer Chemother Rep 55:303-307, 1971PubMedGoogle Scholar
  115. 115.
    Broder LE, and Carter SK. Pancreatic islet cell carcinoma. II Results of therapy with streptozotocin in 52 patients. Ann Intern Med, 79:108-118, 1973PubMedGoogle Scholar
  116. 116.
    Loftus L, Cuppage FE, Hoogstraten B. Clinical and pathological effects of streptozotocin. J Lab Clin Med. 84:407-413, 1974PubMedGoogle Scholar
  117. 117.
    Myerowitz RL, Sartiano GP, and Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin. Report of a patient with multiple hormone-secreting islet cell carcinoma. Cancer, 38:1550-1555, 1976PubMedGoogle Scholar
  118. 118.
    Anderson T, Schein PS, McMenamin MG, and Gooney DA. Streptozotocin diabetes. Correlation with extend of depression of pancreatic islet nicotinamide adenine dinucleotide. J Clin Invest 54:672-677, 1974PubMedGoogle Scholar
  119. 119.
    Schein PS and Loftus S. Streptozotocin: depression of mouse liver pyridine nucleotides. Cancer Res 28:1501-1506, 1968PubMedGoogle Scholar
  120. 120.
    Horton L, Fox C, Corrin B and Sönksen PH. Streptozotocin-induced renal tumors in rat.Br J Cancer. 36:692-699, 1977Google Scholar
  121. 121.
    Rakieten N, Gordon BS, Cooney DA, Davis RD and Schein PS. Renal tumorigenesis action of streptozotocin [NSC-85998] in rats. Cancer Chemother Rep. 52:563-567, 1968PubMedGoogle Scholar
  122. 122.
    Dumontet C, Thieblemont C, Espinouse D, Bouafia F, Hequet O, Salles G, Coiffier B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin’s lymphoma and two or three adverse prognostic factors. Leukemia. 2000 Dec;14[12]:2159-65PubMedGoogle Scholar
  123. 123.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C. Phase II trial of subcutaneous in- terleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm. 2000 Oct;15[5]:487- 94PubMedGoogle Scholar
  124. 124.
    Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000 Dec;26[6]:397-409PubMedGoogle Scholar
  125. 125.
    Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol. 2000 May;53[5]:458- 64PubMedGoogle Scholar
  126. 126.
    Spitzer G, Dickie KA, Litam Y et al. High-dose combination of chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer, 45:3075-3085, 1980PubMedGoogle Scholar
  127. 127.
    Olivero VT, Toxicology and pharmacology of the nitrosoureas. Cancer Chemother rep. 4[3]:13-20, 1973Google Scholar
  128. 128.
    Wheeler GP, A review of studies on the mechanism of action of tne nitrosoureas. In [Sartorelli AC ed.] Cancer Chemotherapy, volume 30, Washingtoon, DC:American Chemical Society.pp87-119, 1976Google Scholar
  129. 129.
    Oliverio VT. Toxicology and pharmacology of the nitrosoureas. Cancer Chemother Rep part 3 4:13-20, 1973Google Scholar
  130. 130.
    De Vita VT, Carbone PP, Owens AH, Gold GL, Krant MJ, and Edmonson J. Clinical trials with 1, 3-bis [2-chloroethyl]-1-nitrosourea, NSC 409962. Cancer Res 25:1876-1881, 1965PubMedGoogle Scholar
  131. 131.
    Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973 Feb;33[2]:226-33PubMedGoogle Scholar
  132. 132.
    Goupil A, Baglin A, Clavel B, Verger C, Fritel D. Chronic renal failure after CCNU treatment [author’s transl]. Nouv Presse Med. 1980 Nov 1;9[41]:3069-70PubMedGoogle Scholar
  133. 133.
    Harmon WE, Cohen HJ, Schneeberger EE, Grupe WE Chronic renal failure in children treated with methyl CCNU. N Engl J Med. 1979 May 24;300[21]:1200-3PubMedGoogle Scholar
  134. 134.
    Nichols WC, Moertel CG. Nephrotoxicity of methyl CCNU. N Engl J Med. 1979 Nov 22;301[21]:1181PubMedGoogle Scholar
  135. 135.
    Schacht RG, Feiner HD, Gallo GR, Lieberman A, Baldwin DS. Nephrotoxicity of nitrosoureas. Cancer. 1981 Sep 15;48[6]:1328-34PubMedGoogle Scholar
  136. 136.
    Silver HKB, and Morton DL. CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Trea Rep, 63:226- 227, 1979Google Scholar
  137. 137.
    Berglund J, Progressive renal insuffisancy after CCNU therapy. Läkartidningen 77:1760, 1980PubMedGoogle Scholar
  138. 138.
    Schacht RG, Feiner HD, Gallo GR, Liebermann A and Baldwin DS. Nephrotoxicity of Nitrosoureas. Cancer 48:1328-1334, 1981PubMedGoogle Scholar
  139. 139.
    Liegler DG, Henderson ES, Hahn MA and Oliverio VT. 1989. The effect of organic acids on renal clearance of methotrexate on man. Clin Pharmacol Ther. 10.849-857.Google Scholar
  140. 140.
    Patel OD, Morgenthaler FR, Khazei AM, Grimaidi R and Watkins E. 1969. Methetrexate excretion patterns and renal toxicity. Arch Surg 98:305-308.PubMedGoogle Scholar
  141. 141.
    Balis FM, Savich JL, and Bleyer WA. 1983. Pharmacokinetics of oral methotrexate in children. Cancer Res. 43:2342-2345.PubMedGoogle Scholar
  142. 142.
    Shen DD and Azarnoff DL. 1978. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 8:1-18.Google Scholar
  143. 143.
    Breithaupt H and Kuenzlen E. 1982. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high- dose methotrexate. Cancer Treat Rep. 66:1733-1741.PubMedGoogle Scholar
  144. 144.
    Winograd B, Lippens RJJ, Oosterbaan MJM, Dirks MJM, Vree TB and van der Kleijn E. 1986. Renal excretion and pharmacokinet- ics of methotrexate and 7-hyfroxymethotrexate following a 24 hours high dose infusion of methotrexate in children. Eur J Clin Pharmacol. 30:231-238.PubMedGoogle Scholar
  145. 145.
    Jacobs SA, Stoller RG, Chabner BA, and Johns DG. 1977. Dose-dependent metabolism of methotrexate in man and Rhesus monkey. Cancer Treat Rep, 61:651-658.PubMedGoogle Scholar
  146. 146.
    Pearson ADJ. Mills S, Amineddine HA, Long DR, Craft AW and Chessels JM. 1987. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 20:243-247.PubMedGoogle Scholar
  147. 147.
    Sonneveld P, Schultz FW, Nooter K and Hahlen K. 1986. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate in plasma and bone marrow of children receiving, low-doses oral methotrexate. Cancer Chemother Pharmacol 18:111-118.PubMedGoogle Scholar
  148. 148.
    Rieselbach RF and Garnick MB. 1988. Renal diseases indiced by antineoplastic agents. In Schrier RW, Gottschalk CW. [eds], Diseases of the kidney [Fourth edition], Boston, MA Little Brownand Company.pp 1275-1299.Google Scholar
  149. 149.
    Pittman SW, and Frei E. 1977. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; phar- macokinetics in the CNS, and use in CNS non Hodgkin’s lymphoma. Cancer Treat Rep. 61:695-701.Google Scholar
  150. 150.
    Glode LM, Pitman SW and Ensminger WD. 1979. A phase I study of high dose of aminopterin with leucoverin rescue in patients with advanced metastatic tumors. Cancer Res. 39:3707-3714.PubMedGoogle Scholar
  151. 151.
    Link DA, Fosberg MT and Ingelfinger JR. 1976. Renal toxicity of high-dose methotrexate. Pediatr Res. 10:455 [abstr].Google Scholar
  152. 152.
    Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 1986, I:256-258.Google Scholar
  153. 153.
    Kremer JM and Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate [MTX]pharmacokinetics: Impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol. 1995. 22:2072-2277.PubMedGoogle Scholar
  154. 154.
    Pitman SW, Parker LM, Tattersall MNH, Jaffe N, Frei E. Clinical trial of high-dose methotrexate with citrovorum factor-toxicologic and therapeutic observations. Cancer Chemother Rep. 1975. 6:43-49.Google Scholar
  155. 155.
    Abelson HT, Fosburg MT, Beardsley GP. Methotrexate-induced renal impairment. J Clin Oncol 1983. 1:208-216.PubMedGoogle Scholar
  156. 156.
    Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion wih sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med. 1987. 82:350-352.PubMedGoogle Scholar
  157. 157.
    Relling MV, Stapelton BF, Ochs J, Jones DB, Meyer W, Wainer IW, Crom WR, McKay CP and Evans WE. Removal of methotrexate, leucoverin and their metabolites by combined hemodialysis and hemoperfusion. Cancer, 62.884-888, 1988.PubMedGoogle Scholar
  158. 158.
    Remuzzi G, Galbusera M, Salvadori M, et al. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int 49: 282-6, 1996.PubMedGoogle Scholar
  159. 159.
    Flombaum CD, Mouradian JA, Casper ES, et al. Thrombotic microangiopathy as a complication of long-term therapy with gem- citabine. Am J Kidney Dis 33: 555-62, 1999.PubMedGoogle Scholar
  160. 160.
    Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85: 2023-32, 1999.PubMedGoogle Scholar
  161. 161.
    Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemo- therapy-treated patients with adenocarcinoma. Cancer 58: 1428-36, 1986.PubMedGoogle Scholar
  162. 162.
    Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 16: 151-61, 2005.PubMedGoogle Scholar
  163. 163.
    Flombaum CD. Gemcitabine Nephrotoxicity and the Hemolytic Uremic Syndrome (HUS): Report of 29 Cases from a Single Institu- tion. J Am Soc Nephrol, 2005, 777°. Poster SA-PO1008.Google Scholar
  164. 164.
    Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34: 140-7, 1997.PubMedGoogle Scholar
  165. 165.
    Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 24: 161-77, 1987.PubMedGoogle Scholar
  166. 166.
    Monteagudo J, Pereira A, Roig S, et al. Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome. Am J Hematol 33: 46-9, 1990.PubMedGoogle Scholar
  167. 167.
    Zeigler ZR, Rosenfeld CS, Andrews DF 3rd, et al. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplantassociated thrombotic microangiopathy (BMT-TM). Am J Hematol 53: 213-20, 1996.PubMedGoogle Scholar
  168. 168.
    Hollenbeck M, Kutkuhn B, Aul C, et al. Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 13: 76-81, 1998.PubMedGoogle Scholar
  169. 169.
    Sens YA, Miorin LA, Silva HG, et al. Acute renal failure due to hemolytic uremic syndrome in adult patients. Ren Fail 19: 279-82, 1997.PubMedGoogle Scholar
  170. 170.
    Mergenthaler HG, Binsack T, Wilmanns W. Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorour- acil-adriamycin-mitomycin C combination chemotherapy. Oncology 45: 11-4, 1988.PubMedGoogle Scholar
  171. 171.
    van Hazel GA, Scott M, Rubin J, Moertel CG, Eagan RT, O’Connell MJ and Kovach JS. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep, 67:805-810, 1982Google Scholar
  172. 172.
    Schilder RB, Young JD, Ratanatharathorn V, Karanes C and Baker LH. Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol, 13:186-190, 1984Google Scholar
  173. 173.
    Erlichman C, Rauth AM, Battistella R and Fine S. Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma. Can J Physiol Pharmacol, 65:407-411, 1987PubMedGoogle Scholar
  174. 174.
    Lelesne JB, Rothschild N, Erickson B, Koreu S, Sisk R, Keller J, Arbus M, Wooley P, Chiazze L, Schein PS, and Neefe JR. Cancer-as- sociated hemolytic-uremic syndrome: analysis of 85 cases from the national registry. J Clin Oncol, 7:781-789, 1989Google Scholar
  175. 175.
    Cantrell JE, Phillips TM, and Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin chemo- therapy. J Clin Oncol, 3:723-734, 1985PubMedGoogle Scholar
  176. 176.
    Hanna WT, Krauss S, Regester RF and Murphy WM. Renal disease after Mitomycin C therapy. Cancer, 48:2583-2588, 1981PubMedGoogle Scholar
  177. 177.
    Gulati SC, Sordillo P, Kempin S, Reich L, Magill GB, Scheiner E and Clarkson B. Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer, 45:2252-2257, 1980PubMedGoogle Scholar
  178. 178.
    Bayle F, Vialtel P, Bastrenta F, Swiercz P, Dechelette E, Pin I, Carpentier P, Mousseau M, Schaerer R, Couderc P, Cordonnier D. [Thrombotic microangiopathy and chronic renal failure caused by mitomycin C in 4 women treated for breast cancer]. Nouv Presse Med. 1982 Jun 26;11[30]:2300-1PubMedGoogle Scholar
  179. 179.
    Hanna WT, Krauss S, Rolland FR, Murphy WM. Renal disease after mitomycin C therapy. Cancer, 1981, 48:2583-88.PubMedGoogle Scholar
  180. 180.
    LiuK, Mittelmann A, Sproul RR, and Elias EG. Renal toxicity in man treated with mitomycin C Cancer, 28:1314-1320, 1971Google Scholar
  181. 181.
    Lyman NW, Michaelson R, Viscuso RL, Winn R, Mulgaonakar S, Jacobs MG. Mitomycin-induced hemolytic-uremic syndrome. Successful treatment with corticosteroids and intense plasma Arch Intern Med. 1983 Aug;143[8]:1617-8.Google Scholar
  182. 182.
    Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med. 1984 Jul;101[1]:41-4.PubMedGoogle Scholar
  183. 183.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghause SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med, 1985, 313:1485-1491.CrossRefGoogle Scholar
  184. 184.
    Law TM, Motzer RJ, Gluck L et al. Phase III randomized trial of interleukine-2 with or without lymphokine activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 1995, 76: 824-832.PubMedGoogle Scholar
  185. 185.
    Rozenberg SA, Lotze MT et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukine 2 or high dose interleukine 2 alone. N ehg J Med. 1987, 316, 889-897.CrossRefGoogle Scholar
  186. 186.
    Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. Prolonged continuous intravenous infusion interleukin-2 and lymphokine activated killer cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992, 10:960-968.PubMedGoogle Scholar
  187. 187.
    Guleria AS, Yang JC, Topalian SL, et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J Clin Oncol. 1994, 12:2714-2722.PubMedGoogle Scholar
  188. 188.
    Webb DE, Austin HA, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Metabolic and renal effects of Interleukin-2 immu- notherapy for metastatic cancer. Clin Nephrol. 1988, 30 [3]:141-145.PubMedGoogle Scholar
  189. 189.
    Philip T, Mercatello A, Negrier S, Philip I, Rebattu P, Kaemmerlin P, Gaspard M, Tognier E, Combaret V, Bijman JT, et al. Interleukine- 2 with and without LAK cells in renal cell carcinoma: the Lyon first-year experience with 20 patients. Cancer Treat Rev. 1989, 13 [suppA]:91-104.Google Scholar
  190. 190.
    Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid wediated by the systemic administration of recombinant interleukin-2. J Immunol. 1986, 137:1735-1742.PubMedGoogle Scholar
  191. 191.
    Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J. Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron, 1993, 64[1]:114-118.PubMedGoogle Scholar
  192. 192.
    Feinfeld DA, D’Agati Y, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH. Interstitial nephritis in a patient receiving adoptive immuno- therapy with recombinant interleukin-2 and lymphokine-activated killer cells. Am J Nephrol. 1991, 11[6], 489-492.PubMedGoogle Scholar
  193. 193.
    Valsveld LT, van de Wiel-van Kamenade E, de Boer AJ, Sein JJ, Galle MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG. Possible role for cytotoxic lymphocytes in the pathogenesis of acute intertitial nephritis after recombinant interleukin-2 treat- ment for renal cell cancer. Cancer Immunol Immunother. 1993, 36[3]:210-213.Google Scholar
  194. 194.
    Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, and Wiernik PH. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Oncol, 1990, 8[11]: 1839-1846.PubMedGoogle Scholar
  195. 195.
    Wills RJ, Clinical pharmacokinetics of interferons. Clin Pharmacokinet, 1990, 19:390-399.PubMedGoogle Scholar
  196. 196.
    Grimbert P, Deray G, Lebon P, Faucher C, Malingre P, Raymond F, Petitclerc T, and Jacobs C. Pharmacokinetics of recombinant leukocyte interferon in a patient on continuous ambulatory peritoneal dialysis. Am J Nephrol, 1995, 15:175(2).PubMedGoogle Scholar
  197. 197.
    Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, and Canal P. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing hemodialysis or with normal renal function. Clinical implications. J Am Soc Nephrol. 1998, 9:2344-2348.PubMedGoogle Scholar
  198. 198.
    Bocci V, Pacini A, Muscettola M, Paulesu L, Pessina GP, santiano M, Viano AI. Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res, 1981, 3: 347-352Google Scholar
  199. 199.
    Bailly F, Mattei A, SiAhmed SN, Trepo C. Uncommon side-effects of interferon. J Viral Hep, 1997, 4 [suppl 1]: 89-94.Google Scholar
  200. 200.
    Gresser I, Maury M, Tovey M, Morel Maroger L, Pontillon F. Progressive glomerulonephritis in mice treated with interferon prepa- ration at birth. Nature. 1976. 263:420-422.PubMedGoogle Scholar
  201. 201.
    Morel-Maroger L, Sloper JC, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest. 1978 Nov;39(5):513-22.PubMedGoogle Scholar
  202. 202.
    Quesada J et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986, 4:234.PubMedGoogle Scholar
  203. 203.
    Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 4(2):234-43.PubMedGoogle Scholar
  204. 204.
    Miranda-Guardiola F, Fdez-Llama P, Badia J, Botey A, Estruch R, Darnell A, Rozman C and Revert L. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol. Dial Transplant, 1995, 10:1441-1443.PubMedGoogle Scholar
  205. 205.
    Nair S, Ernstoff M, Bahnson R, Arthur S, Johnston J, Downs M, Neuhart J, and Kirkwood J. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology, 1992, 39 (2), 169-172.PubMedGoogle Scholar
  206. 206.
    Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N Engl J Med. 1984 5;310(1):32-5.CrossRefGoogle Scholar
  207. 207.
    Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha IIB in patients with myeloproliferative syndromes. Renal Failure, 91:13:87-93.Google Scholar
  208. 208.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-42PubMedGoogle Scholar
  209. 209.
    Kabbinavar, F, Hurwitz, HI, Fehrenbacher, L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV ) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 21:60-5, 2003PubMedGoogle Scholar
  210. 210.
    Genentech: Avastin. labeling Text, FDA Approval Date: September 2005Google Scholar
  211. 211.
    Levine, RJ, Maynard, SE, Qian, C. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 350:672-83, 2004PubMedGoogle Scholar
  212. 212.
    Simon, M, Grone, HJ, Johren, O. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol, 268:F240-50, 1995.PubMedGoogle Scholar
  213. 213.
    Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis. 1991 Feb;17(2):144-8.PubMedGoogle Scholar
  214. 214.
    Eremina, V, Sood, M, Haigh, J. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest, 111:707-16, 2003.PubMedGoogle Scholar
  215. 215.
    Mathieson, PW: How much VEGF do you need? J Am Soc Nephrol, 17:602-3, 2006.PubMedGoogle Scholar
  216. 216.
    Miller, KD, Chap, LI, Holmes, FA. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol, 23:792-9, 2005.PubMedGoogle Scholar
  217. 217.
    Markowitz, GS, Appel, GB, Fine, PL. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamid- ronate. J Am Soc Nephrol, 12:1164-72, 2001.PubMedGoogle Scholar
  218. 218.
    Johnson, DH, Fehrenbacher, L, Novotny, WF. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol, 22:2184-91, 2004.PubMedGoogle Scholar
  219. 219.
    Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.PubMedGoogle Scholar
  220. 220.
    Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O’Dwyer PJ. Mechanisms of hypertension as- sociated with BAY 43-9006. J Clin Oncol. 2006 Mar 20;24(9):1363-9.PubMedGoogle Scholar
  221. 221.
    Rini B, Rixe O, Bukowski R, et al. (2005) AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Proc (abstract 4509).Google Scholar
  222. 222.
    Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006 Sep;113(9):1522.e1-1522.e14.Google Scholar
  223. 223.
    Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006 Jun 7;295(21):2516-24.PubMedGoogle Scholar
  224. 224.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 1;24(16):2505-12.PubMedGoogle Scholar
  225. 225.
    Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006 Jan 1;24(1):25-35.PubMedGoogle Scholar
  226. 226.
    Yang, R, Thomas, GR, Bunting, S. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol, 27:838-44, 1996.PubMedGoogle Scholar
  227. 227.
    Neagoe, PE, Lemieux, C Sirois, MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem, 280:9904-12, 2005.PubMedGoogle Scholar
  228. 228.
    Henry, TD, Annex, BH, McKendall, GR. The VIVA trial. Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation, 107:1359-65, 2003.PubMedGoogle Scholar
  229. 229.
    Chen, S, Lee, JS, Iglesias-de la Cruz, MC. Angiotensin II stimulates alpha3 (IV ) collagen production in mouse podocytes via TGF- beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant, 20:1320-8, 2005.PubMedGoogle Scholar
  230. 230.
    Mares, JE, Worah, S, Mathew, SV. Increased rates of hypertension (HTN) among patients with advanced carcinoid treated with bevacizumab. the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO).Abstract No: 4087, 2005.Google Scholar
  231. 231.
    Ginsberg, JM, Chang, BS, Matarese, RA. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med, 309:1543-6, 1983.PubMedCrossRefGoogle Scholar
  232. 232.
    Cohen E. Radiation nephropathy after bone marrow transplantation. Kidney International, 2000, 58:903-918.PubMedGoogle Scholar
  233. 233.
    Redd BL. Radiation nephritis: review, case report and animal study. Roentgenol. 1960, 83:88.Google Scholar
  234. 234.
    Phillips TL, Wharam MD, Margolis LW. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer, 1975, 35:1678-1684.PubMedGoogle Scholar
  235. 235.
    Kelly CJ and Neilson EG. Intertitial diseases. In Brenner & Rector’s, Ed by Barry B. Brenner, WB Saunders Company, Phildelphia, 1655-1679, Vth edition, 1996.Google Scholar
  236. 236.
    Jaenke RS, Robbins MEC, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. Capillary endothelium: target site of renal radiation injury. Lab Invest 1993, 68:396-405.PubMedGoogle Scholar
  237. 237.
    Rubin P, Casarett GW. Clinical Radiation pathology. Philadelphia, Saunders, 1968, pp 293-333.Google Scholar
  238. 238.
    Robbins MEC, Hopewell JW: Physiological factors effecting renal radiation tolerance: A guide to the treatment of late effects. Br J Cancer, 1986, 53:265-267.Google Scholar
  239. 239.
    Cohen EP, Fish BL, Moulder JE: Treatment of radiation nephropathy with captopril. Radiat Res. 1992, 132: 346-350.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Corinne Isnard-Bagnis
    • Vincent Launay-Vacher
      • Svetlana Karie
        • Gilbert Deray

          There are no affiliations available

          Personalised recommendations